Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)
{{output}}
Introduction: Osimertinib has become standard of carein 1 LEGFR-mutated(mt)mNSCLC following the FLAURA trial.However, limited data are available on the effect of osimertinib dose-reductionon outcomes compared tofull-dose. ... ...
